Table 3

Durable attainment of treatment targets based on time exposure thresholds with high specificity for organ damage-free and severe flare-free progression in patients with active moderate-to-severe SLE

Outcome: organ damage accrual*Outcome: severe flare(s)†
Frequency‡ RR (95% CI)§ Specificity¶ RR (95% CI) Specificity
DORIS ≥50% of time**23.3%0.61 (0.43 to 0.86)††85.2%0.39 (0.25 to 0.62)‡‡95.1%
LLDAS ≥60% of time41.7%0.58 (0.45 to 0.77)‡‡73.3%0.35 (0.26 to 0.47)‡‡88.1%
DORIS ≥24 months§§20.2%0.53 (0.37 to 0.75)‡‡86.1%0.44 (0.28 to 0.69)‡‡96.9%
LLDAS ≥36 months28.0%0.58 (0.44 to 0.76)‡‡81.2%0.34 (0.22 to 0.52)‡‡96.9%
  • Cumulative time (months) of sustained attainment of each target.

  • *Any increase in SDI since the inclusion visit.

  • †According to the SELENA-SLEDAI Flare Index.

  • ‡Proportion (%) of the cohort who meet each target threshold.

  • §RR with 95% CI obtained from the generalised linear model treating organ damage accrual and severe flare(s) as dependent variables and each target cut-off as predictor (adjusting for gender, age and duration of observation).

  • ¶Obtained from 2×2 contingency tables of damage-free and severe flare-free outcome by each target cut-off.

  • **Cumulative time (percentage of total observation period) in each target.

  • ††P=0.005.

  • ‡‡P<0.001.

  • §§Cumulative time (months) of sustained attainment of each target.

  • DORIS, Definition of Remission in SLE; LLDAS, Lupus Low Disease Activity State; RR, relative risk; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index.